Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on April 29, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Intent to Sole Source - Biolegend Oliogos

Closed
NOI-CC-OLAO-26-004813Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414
New
Federal
iNDI FA13.1J Cell Lines Expansion and Distribution for the iPSC Neurodegenerative Disease Initiative (iNDI) ProjectThe Department of Health and Human Services, through the National Institutes of Health's National Institute on Aging, intends to award a sole source contract to The Jackson Laboratory for the expansion, quality control, biobanking, and distribution of isogenic Alzheimer’s disease and related dementias induced pluripotent stem cell lines as part of the iPSC Neurodegenerative Disease Initiative (iNDI) Project. This contract will focus on providing up to 936 specific iPSC lines, including 486 FA13.1J female SNV lines and 450 lines across 25 high-priority SNV trios, adhering to iNDI protocols for quality and expansion. The Jackson Laboratory is uniquely qualified for this contract as it currently houses the existing distribution infrastructure and has demonstrated successful past performance in supporting NIH’s iNDI requirements. The contract is planned to be a firm-fixed-price agreement with a performance period starting September 1, 2026, for a base year and up to three option years, ending August 31, 2030. The primary place of performance will be the contractor’s facility in Bar Harbor, Maine. While this notice signals the intent for a sole source award, other capable sources may submit capability statements demonstrating their ability to meet the outlined requirements, including supply of the specific cell lines, adherence to quality protocols, product and web content creation, and public distribution via an established platform. Responses must be submitted electronically by June 23, 2026, and the Government reserves the right to consider all responses but is under no obligation to initiate a competitive procurement.
National Institutes Of Health Olao

POSTED

6 days ago

DEADLINE

in 7 days

AI Contract Overview

Show more

The National Institutes of Health Clinical Center (NIH-CC) has issued a Notice of Intent to negotiate a contract on a sole source basis with Biolegend for the procurement of custom oligonucleotides. These oligonucleotides are required by the PACT team at the Clinical Center Enterprise (CCE) to support single cell copy number analysis using the Tapestri instrument, specifically for CAR-T cell product clinical quality control assays. This acquisition is justified under the statutory authority allowing sole source procurement when only one responsible source exists that can fulfill the agency's needs, as outlined in 41 U.S.C. 253(c)(1) and FAR 6.302-1. This notice clarifies that it is not a request for proposals but invites any other capable suppliers to submit capability statements by May 8, 2026, at 12:00 PM Eastern time for consideration. All submissions received by this deadline will be reviewed, but the government retains full discretion whether or not to proceed with competition. The solicitation number for this acquisition is NOI-CC-OLAO-26-004813, and the contract will be performed in Bethesda, Maryland, under NAICS code 325414. The NIH has indicated no set-aside provisions are being utilized for this procurement.

General Info

NIH plans sole source contract with Biolegend for custom oligonucleotides supporting CAR-T cell assays.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing View NAICS

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
ContactsNo contacts available
OfficeBethesda, MD, 20892, US
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health
Office AddressBethesda, MD, 20892, US
ContactsNo contact information available

Full Description

Show more

This is a Notice of Intent, not a request for proposal.  The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Biolegend.


Acquisition Description:


Custom Oligios needed by PACT team at CCE to do single cell copy number analysis with Tapestri instrument for CAR-T cell products to support clinical QC assay.


The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.  All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-26-004813) by 12:00 PM eastern standard time on 05/08/2026 to: valerie.gregorio@nih.gov.


All responses received by the closing date of this synopsis will be considered by the Government.  A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.